- Home
- RBLX vs BIIB Comparison
RBLX vs BIIB Comparison
Compare RBLX & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBLX
- BIIB
- Stock Information
- Founded
- RBLX 2006
- BIIB 1978
- Country
- RBLX United States
- BIIB United States
- Employees
- RBLX N/A
- BIIB N/A
- Industry
- RBLX EDP Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- RBLX Technology
- BIIB Health Care
- Exchange
- RBLX Nasdaq
- BIIB Nasdaq
- Market Cap
- RBLX 38.7B
- BIIB 25.1B
- IPO Year
- RBLX 2021
- BIIB 1991
- Fundamental
- Price
- RBLX $59.56
- BIIB $150.14
- Analyst Decision
- RBLX Buy
- BIIB Buy
- Analyst Count
- RBLX 23
- BIIB 26
- Target Price
- RBLX $54.77
- BIIB $248.00
- AVG Volume (30 Days)
- RBLX 7.3M
- BIIB 1.6M
- Earning Date
- RBLX 02-05-2025
- BIIB 02-11-2025
- Dividend Yield
- RBLX N/A
- BIIB N/A
- EPS Growth
- RBLX N/A
- BIIB 10.05
- EPS
- RBLX N/A
- BIIB 11.06
- Revenue
- RBLX $3,363,735,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- RBLX $59.22
- BIIB N/A
- Revenue Next Year
- RBLX $20.42
- BIIB N/A
- P/E Ratio
- RBLX N/A
- BIIB $13.47
- Revenue Growth
- RBLX 27.98
- BIIB N/A
- 52 Week Low
- RBLX $29.55
- BIIB $145.07
- 52 Week High
- RBLX $61.77
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- RBLX 59.59
- BIIB 31.81
- Support Level
- RBLX $57.89
- BIIB $145.07
- Resistance Level
- RBLX $60.63
- BIIB $149.92
- Average True Range (ATR)
- RBLX 2.30
- BIIB 3.57
- MACD
- RBLX -0.26
- BIIB 0.18
- Stochastic Oscillator
- RBLX 53.90
- BIIB 22.27
About RBLX Roblox Corporation
Roblox operates an online video game platform with 80 million daily active users that lets young gamers create, develop, and monetize games (or "experiences") for other players. The firm offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning $3.5 billion in bookings in 2023 through in-game purchases and advertising while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers than creating new games or franchises.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.